High-Throughput Virtual Screening of 4487 flavonoids: New insights on
the structural inhibition of SARS-CoV-2 Main Protease
Gabriel M Jim√©nez-Avalos¬π¬ß, Ana Paula Vargas-Ruiz¬π¬ß, Nicol√°s E Delgado-Pease¬π¬ß, Gustavo E
Olivos-Ram√≠rez¬π, Patricia Sheen-Cortavarr√≠a¬π, Manolo Fernandez¬≤, Mirko J Zimic-Peralta¬π ¬≤*, for
the COVID UPCH-FARVET Research Group in Peru.
AFFILIATIONS:
1. Laboratorio de Bioinform√°tica y Biolog√≠a Molecular, Facultad de Ciencias y Filosof√≠a,
Departamento de Ciencias Celulares y Moleculares, Universidad Peruana Cayetano Heredia,
Lima, Per√∫.
2. FARVET. Chincha, Per√∫.
¬ß These authors contributed equally.
*Corresponding authors: mirko.zimic@upch.pe
ABSTRACT
COVID-19 presents a great threat to public health worldwide and the infectious agent SARS-CoV2 is currently the target of much research aiming at inhibition. The virus‚Äô main protease is a
dimeric enzyme that has only recently begun to be thoroughly described, opening the door for
virtual screening more broadly. Here, a PAIN-filtered flavonoid database was screened against
four sites of the protease: a free (normal) conformation of the Substrate Binding Site (NSBS), an
induced-fit state of the SBS (ISBS), a Dimerization Site (DS) and a Cryptic Site (CS). The mean
binding energy of the top five ligands from each site were -9.52, -11.512, -7.042 and -10.348
kcal/mol for the NSBS, the ISBS, the DS and the CS, respectively. For the DS and CS, these top
five compounds were selected as candidates to bind their respective site. In the case of SBS, the
top 30 ligands with the lowest binding energies from NSBS and ISBS were contrasted and the
ones present in both lists were selected as the final candidates. The final list was: Dorsilurin E
(FL3FQUNP0001), Euchrenone a11 (FL2FALNP0014), Kurziflavolactone C (FL2FA9NC0016),
Licorice glycoside E (FL2F1AGSN001) and Taxifolin 3'- (6"-phenyl- acetylglucoside)
(FL4DACGS0020) for the SBS; Sanggenol O (FL2FALNP0020), CHEMBL2171573, Kanzonol E
(FL3F1ANP0001), CHEMBL2171584 and Abyssynoflavanone VI (FL2FACNP0014) for DS and
CHEMBL2171598, CHEMBL2171577, Denticulaflavanol (FL5FAANR0001), Kurzichalcolactone
(FL1CA9NC0001) and CHEMBL2171578 for CS. Virtual screening integrated several confirmation
methods, including cross-docking assays and positive and negative controls. All 15 compounds
are currently subjected to molecular dynamics so as to theoretically validate their binding to the
protease.

1. INTRODUCTION
The Coronavirus Disease-2019 (or COVID-19) was first reported in late December 2019 in
Wuhan, PRC (1). First identified as a kind of pneumonia, common symptoms are fever, cough
and myalgia or fatigue, with less common symptoms ranging from sputum production,
headache, haemoptysis and diarrhoea (2). Later developments included lymphopenia and
dyspnoea. These findings point at a clinical description akin to that of severe acute respiratory
syndrome (SARS) coronavirus (2,3).
Nonetheless, finding a treatment for viral diseases seldom is a serendipitous event. It requires
systematic narrowing of candidates, usually by virtual screening (VS) methods. VS has been able
to provide ample and robust support for drug discovery, design and evaluation efforts (4,5) with
a variety of specialized options (6) as the in silico counterpart for high throughput screening.
These are often coupled in sequential or parallel arrays: hierarchical VS (HLVS) or parallel VS
(PVS), respectively (5). This development was inevitable given both the relentless growth in
library sizes (7,8) and the equally vertiginous development in the virtual screening par
excellence, molecular docking (9‚Äì11). HLVS has been invaluable in sieving through large
databases of small organic molecules to find drugs for viral diseases. This is invaluable for the
development of new contenders as the current pharmacological options are rendered obsolete
by high viral genome variability (12). Such developments of new drugs against virus through VS
include influenza (13), ebola (14) and dengue (15).
Trying SARS-CoV drugs against SARS-CoV-2 has been proposed (16) given the close genomic
proximity between them (17). Unfortunately, those drugs have not been universally approved
for treatment and usually remain stagnant on clinical or pre-clinical trials (18). Moreover, even
small differences in amino acid sequence can affect drug efficaciousness (19). Unsurprisingly,
the appeal of VS approaches against SARS-CoV-2 has not eluded scientists during this pandemic.
Most have tried to evaluate the repurposing of existing drugs (16,20‚Äì22). Nevertheless, these
research lines run the risk of facing adverse effects later on for employing drugs designed for
other sites (23). Other papers have focused on the active site of SARS-CoV-2 main protease
(MPRO) (16,24), but this emphasis could be too restrictive since dimerization inhibition is a
plausible alternative (25,26). Furthermore, the occurrence of cryptic sites is a possibility worth
exploring. Loosely put, a binding site can be described as cryptic if identifiable in the ligandbound while not in the unbound structure of a given protein (27). These locations pose a
promising way to increase the druggability of a target protein (28,29). Therefore, an exhaustive
VS of readily available, pharmacologically safe, new small molecules targeted at more than one
site in the MPRO is the aim of this paper.
Flavonoids are one such group of small molecules produced as secondary metabolites in fungi
and plants. They present a common diphenyl structure coupled with a heterocyclic ring and with
various hydroxyl phenolic groups with great chelation capacity for iron and other transition
metals. Especially relevant to this research is the antiviral activity of flavonoids. The flavonoid
apigenin combined with acyclovir has a significant effect on types 1 and 2 herpes virus simplex
known since the early 1990s (30). Remarkably, 64 flavonoids were previously screened against
the SARS-CoV-1 3CL (chymotrypsin-like) protease (3CLpro) with promising results (31).
Furthermore, the 3CLpro from SARS-CoV-1 differs from the SARS-CoV-2 MPRO in but 12 amino
acids, which justifies a further attempt for flavonoid inhibition against this second protein (32).
In that vein, a handful of flavonoids have been recently tried in silico against SARS-CoV-2 spike
protein (33), which leaves open the questions as to what other flavonoids could prove useful.
All this considered, the panoply of flavonoids available in many online databases presents itself
as an ideal opportunity to fuel a new quest for SARS-CoV-2 inhibition.

1

2. METHODS
2.1. Generation of 3D structures and selection of putative binding sites
2.1.1. Library preparation
An exhaustive search was conducted for compounds reported as flavonoids in the Metabolomics
(34) database with an inhouse R script for web scraping using the rvest package (35). Similarly,
the online databases DrugBank (36), CHEMBL (37) and PubChem (38) were subject to an
automated search. For these last websites, searches were performed manually with the key
words flavonoid, flavonoids and flavo, except for DrugBank, where the whole base was
downloaded. Then, all four bases were standardized to show a unique ID, SMILE and online
source for each compound. All four databases from DrugBank, PubChem, CHEMBL and
Metabolomics were merged through an R script, additionally parsing the complete database
through the same means in order to remove compounds with molar weight under 180 kDa.
Compounds with identical SMILES were removed for each database.
2.1.2. PAINs filtering
The database was then uploaded to FAFDrugs4 server (39) for further processing. Two SMILES,
even though literally distinct, may be synonyms for the same compound. FAFDrugs4 reads each
SMILE and interprets the code into structure in order to exclude synonymic SMILEs. Next, all
screening tools to identify and purge pan-assay interference compounds (PAINS) offered by the
website were employed. A final SMILE database was downloaded and matched for their unique
IDs and online sources.
2.1.3. 3D structure generation.
SMILEs were read and employed to generate .smi files for each compound. Afterwards, these
files worked as blueprints for the generation of .sdf files containing the bidimensional structure
of each compound through the package OpenBabel v.3.1.1 (40). These in turn were the starting
point for the three-dimensional structures, each of which was subject to a 25000-step
minimization through the steepest-descent method (41). Finally, the resulting .sdf files of the
minimized compounds were converted to .pdb format for their docking preparation. All these
steps were performed automatically through an inhouse Python script.
2.1.4. Electrochemical and structural assessment of putative binding sites
Three sites of interest were identified for docking targeting: the substrate-binding site (SBS), the
dimerization site (DS) and the cryptic site (CS). The first two were chosen after bibliographic
consideration (32,42) while the cryptic site was originally predicted using CryptoSite (28).
Collectively, they are referred to as ‚Äúputative binding sites‚Äù.
pH is not homogeneously distributed along the protein surface, given that pH in each region is
determined by the microenvironment fostered by the residues specific to that region. In order
to analyse these microenvironments, server PDB2PQR (43) was employed. Said program assigns
the appropriate protonation states to an input protein‚Äôs residues, presently the apo-structure
of MPRO excised from PDB ID: 6LU7. This software takes into account the surrounding residues
as well as the macro-system pH, which in this case was set to 7.4 (physiological pH). Thus, the
protonation states of key histidines were employed to infer the microenvironment pHs for the
three putative binding sites and where they stood in comparison to the general pH of the
system.

2

Each putative binding site had its respective solvent-accessible surface area (SASA) found in
PyMol v.2.4 (44), using as input the hydrogen-curated structure of MPRO obtained before. All the
regions were scoured for residues capable of establishing strong interactions, aromatic rings and
other relevant moieties. The exact residues which conform the S1‚Äô and S1-S5 subsites of the SBS
region (42,45) were determined by analysis of MPRO-N3 complex (PDB: 6LU7).
2.2. Docking assays
2.2.1. Ligand preparation.
20 random compounds were selected in order to conclude the structure was correctly
represented. Once this was settled, the files were converted from .pdb to .pdbqt format with
the AutodocksTool v.4.2 package (46). All torsions were assigned and Gasteiger charges were
added for all atoms in the compound structures.
2.2.2. Receptor preparation.
MPRO structure was procured in two distinct conformations: a free conformation (PDB: 6YB7) and
another conformation induced by an inhibiting ligand in the active site (PDB: 6LU7). These
structures were independently curated on PDBfixer (47) with the intent of repairing lost atoms
and non-standard residues, as well as for deleting heteroatoms. Using this repaired chains, both
receptors were constructed as dimers from the available protomeric states in their respective
.pdb files (biological assembly) using PyMol software.Then, all receptor structures were
converted to .pdbqt format using the graphic interface found in the AutodockTools v.4.2
package, adding polar hydrogens and Gasteiger charges as well.
2.2.3. Virtual Screening.
For the following procedure, a semiflexible VS (with rigid receptor and flexible ligand) was
conducted so as to assess the possibility of compound interaction with each putative binding
site. For this purpose, Autodock Vina v.1.1.2 (48) software was employed with 24 of
exhaustiveness (49) through a Python script which automated the task.
2.2.3.1.

SBS

In order to reach robust conclusions for SBS-binding compounds, a cross-docking methodology
was followed. To this end, the receptors were free MPRO (PDB: 6YB7) and ligand-induced
conformation MPRO (PDB: 6LU7). All residues conforming the SBS were included within the
volume of the search box. Box coordinates for normal and induced-fit docking were 12.339,
1.287, 23.152 and -15.117, 14.564, 67.870; respectively. Dimensions for both boxes were kept
at 35 √Ö x 35 √Ö x 35 √Ö for minimizing search bias.
2.2.3.2.

DS and CS

Given that no induced conformations were available for DS or CS, no cross-docking was
performed, keeping free MPRO as the receptor. Box coordinates for DS and CS were 1.738, -3.380,
4.457 (22 √Ö √ó 28 √Ö √ó 36 √Ö) and 9.104, 12.126, -6.685 (30 √Ö √ó 40 √Ö √ó 30 √Ö); respectively.

3

2.3. Validation
2.3.1. Validation docking
In order to confirm VS results, the next step was a validation docking (VD) with more exhaustive
parameters using the top 100 best compounds in Autodock-GPU v.4.2 (50). Lamarckian genetic
algorithm (LGA) was used as a global search method, while the local search was directed after
the Solis-Wets algorithm (SWA). The procedure included 25 million evaluations and 150 runs.
Box coordinates were maintained irrespective of each virtual screening, with 0.375 √Ö spacing.
Dimensions were 18.75 √Ö √ó 18.75 √Ö √ó 18.75 √Ö, 22.5 √Ö √ó 30 √Ö √ó 37.5 √Ö, and 30.375 √Ö √ó 40.5 √Ö √ó
30.375 √Ö for the SBS (both NSBS and ISBS), DS and CS VDs, respectively.
For each docking assay, the best pose was selected based on its 2Dscore (51). Briefly, each pose
is assigned a score based on the standard normalization (Zscore) of two variables: binding
energy (ŒîG) and cluster population (Pop). Said score is calculated as follows:
2ùê∑"#$%& = ‚àí1 √ó [ùëç"#$%& (ùõ•ùê∫)] + ùëç"#$%& (ùëÉùëúùëù)

The selected solutions were then ranked according to their binding energies. For the DS and CS
VDs, the top five ligands with the lowest binding energies were selected as hits. In the case of
SBS, the top 30 ligands with the lowest binding energies from the VDs against NSBS and ISBS
were contrasted and the ones present in both lists were selected as hits. Then, their most
favourable pose was extracted using PyMol, converted to .mol2 format and supplemented with
the missing hydrogen atoms using OpenBabel at pH 7.4. The protein-ligand complex was
reconstructed by merging the ligand file with its corresponding hydrogen-curated receptor (see
Section 1.3 above).
2.3.2. Positive and negative controls
It is key to confirm that the docking workflow can replicate the binding event of a known
experimental inhibitor and provide reference values (positive control). To this end, the potent
broad-spectrum non-covalent SARS-CoV-2 inhibitor X77 was chosen as comparative standard.
The ligand (X77) was excised from a X77-MPRO co-crystallized complex (PDB: 6W63) using PyMol,
while the same was done for the receptor (free MPRO) from a N3-MPRO co-crystallized complex
(PDB: 6LU7). Then, the ligand .pdb file was converted into .sdf using OpenBabel v.3.1.1. This file
was curated manually using PyMol again so as to correct bond order and add missing hydrogen
atoms. X77 was then docked against ISBS in order to produce a cross-docking while maintaining
the last VD‚Äôs parameters. The resulting complex was contrasted with the initial structure (PDB:
6W63) by their RMSD using PyMol (52).
Equally important is the capacity of sieving protocols for rejecting inert molecules. These
compounds could exhibit false positives in biochemical assays due to colloidal aggregation
(53,54). This is the case of TDZD-8, which only inhibits MPRO through aggregation (45). Thus, this
molecule is taken as an appropriate negative control to test the efficacy of the present protocol
at excluding unspecific, promiscuous molecules. Again, the docking of this compound follows
the VD protocol explained before.
2.4. Protein-ligand interaction analysis
Protein‚ÄìLigand Interaction Profiler (PLIP) was used with default parameters to further explore
protein-ligand interactions arising from docking (55). Coupled with previous electrochemicalstructural revision, PLIP shed light on the chemical environment surrounding each flavonoid.
4

Regarding the SBS, it is worth mentioning that only the interactions provided by the VD against
ISBS were identified and analysed.
In addition to these steps, the protein-ligand complex .pdb files for each hit (see Section 2.3.1
above) was uploaded to the online service Dr. SASA (56) in order to obtain surface data.
3. RESULTS
3.1. Flavonoid Structural Database
The complete database (before FAFDrug4 filters) included 6696 compounds. The final database
comprised 4887 compounds. SMILE information for every compound sufficed to generate
satisfactory minimized 3-D structures in .pdbqt format. The approximate mean torsion quantity
was 9.73. Exhaustiveness was adjusted to 24 for Vina VS and the number of evaluations was set
to 25 million for the VD as a higher number of torsions requires deeper search standards.
3.2. Cryptic Site Description
Cryptic site prediction was done through CryptoSite, which produces a .pol.pred file containing
prediction scores for every residue. The residue is presumed to have a high probability of
constituting a cryptic site whenever the score is above 10. Out of these, several were also
present in the same region as the SBS or DS boxes or relatively close to their residues. These
were left out for the sake of dynamic independence. The residues comprising CS are Lys5, Met6,
Pro108, Gly109, Arg131, Trp218, Phe219, Tyr239, Glu240, Leu271, Leu272, Leu287, Glu288,
Asp289, Glu290, Arg298, Gln299 and Val303.

5

3.3. Analysis of Putative Binding Sites

Figure 1. The MPRO of SARS-CoV-2 and its putative binding sites. Monomers are in cartoon and surface representations, each one
in a different colour. The region covered by each putative binding site in the green monomer is shown as a black rectangle. Residues
conforming the sites are depicted as sticks along their names. (a) Substrate binding site, with colours representing subregions: red
for S1‚Äô, blue for S1, purple for S2, orange for S3, grey for S4 and cyan for S5. Catalytic residues are marked with an asterisk. (b)
Dimerization site. (c) Cryptic site.

MPRO is a homodimer with a heart-shaped structure (Figure 1). The SBS region of MPRO can be
further subdivided into S1‚Äô and S1-S5 subsites. Respectively, these sites interact with P1‚Äô and P1P5 segments of a generic substrate peptide (42). S1‚Äô is defined to be the catalytic region. Other
segments of the peptide are numbered consecutively, starting from P1‚Äô. According to this
definition, it is possible to map S1‚Äô and S1-S5 subsites by analysing the MPRO-N3 interaction
described elsewhere (45). Shortly, the S1‚Äô subsite comprises His41, Gly143, Ser144 and Cys145;
S1 includes Ser1 (from the other protomer), Phe140, Leu141, Asn142 and His163; S2 consists in
Met49, Tyr54, His164, Asp187 and Arg188; S3 consists in Met165 and Glu166; S4 is constituted
by Leu167, Gln189, Thr190 and Gln192; and S5 encompasses Pro168 and Ala191 (Figure 1a). All
of these residues are part of, but not limited to the ones reported in the literature (32).
Regarding dimensions, SBS has a SASA of 975.013 √Ö2. Two histidine tautomers may exist under
physiological conditions: HSD (protonated in the delta position) with a pKa of 6.7, and HSE
(protonated in the epsilon position) with a pKa of 7.3 (57). In the SBS, three monoprotonated
histidines were found: His41 and His163 (HSD) and His164 (HSE). Apart from histidines, three
amino acids with charged side chains at physiological pH were observed within the site (Table
1). Lastly, Cys145 forms a catalytic dyad with His41.

6

Residue
Ser1*
His41
Met49
Tyr54
Phe140
Leu141
Asn142
Gly143
Ser144
Cys145
His163
His164
Met165
Glu166
Leu167
Pro168
Asp187
Arg188
Gln189
Thr190
Ala191
Gln192
Arg4
Met6
Ser10
Gly11
Glu14
Asn28
Ser139
Phe140
Ser147
Glu166
Glu290
Arg298
Lys5
Met6
Pro108
Gly109
Arg131
Trp218
Phe219
Tyr239
Glu240
Lys271
Lys272
Lys287
Glu288
Asp289
Glu290
Gln299
Val303

Charged
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
+
0
0
0
0
+
0
0
0
0
0
0
0
+
+
0
0
0
+
0
0
0
+
+
+
0
0

Polar
Y
Y
N
N
N
N
Y
N
Y
N
Y
Y
N
Y
N
N
Y
Y
Y
Y
N
Y
Y
N
Y
N
Y
Y
Y
N
Y
Y
Y
Y
Y
N
N
N
Y
N
N
N
Y
Y
Y
Y
Y
Y
Y
N
N

Table 1. Physical-chemical characteristics of residues conforming the putative binding sites. A list of all the residues comprising putative binding sites is provided. Residues are categorized based on their
charge (at physiological pH) and polarity. +: positive charged side chain. -: negative charged side chain. 0: neutral side chain. Y: yes. N: no.

Cryptic

Dimer

Substrate

Site

The following residues constitute the DS with a
joint SASA of 736.627 √Ö2: Arg4, Met6, Ser10,
Gly11, Glu14, Asn28, Ser139, Phe140, Ser147,
Glu166, Glu290 and Arg298 (Figure 1b) (32).
Nine out of 12 residues are polar, which raises
the chances of forming hydrogen bonds with a
ligand. There are no histidines among the
constituting residues, yet His172 and His163
(both as HSD) are found near Ser139, Phe140
and Glu166. It is worth noting that the source
material that predicted SARS-CoV-2 DS inferred
the location of the site based on SARS-CoV-1 DS
(32), therefore their site description is
perfectible by more direct studies. Similar to
the SBS, five amino acids with charged side
chains at physiological pH were observed
(Table 1).
Finally, the CS residues (Figure 1c) jointly make
up a SASA of 665.350 √Ö2. Unlike DS, only half of
the residues were polar. No histidines were
observed inside nor in the near vicinity.
Nevertheless, this site is the most likely to host
saline bonds given the nine residues with
ionizable sidechains found within (Table 1).
3.4. Virtual Screening
The best 100 compounds for each putative
binding site had mean binding energies of 8.89, -10.06, -8.08 and -9.21 kcal/mol for the
NSBS, the ISBS, the DS and the CS, respectively.
Each of these ligands‚Äô sets were selected for a
VD against their respective putative binding
site.
3.5. Validation Docking
Mean binding energies for each site‚Äôs top fivr
were -9.52, -11.512, -7.042 and -10.348
kcal/mol for the NSBS, the ISBS, the DS and the
CS, respectively. After cross-referencing the
NSBS and ISBS top 30, a total of fifteen
compounds were retrieved (Table 2). The final
VD results presented the ligands Dorsilurin E
(FL3FQUNP0001),
Euchrenone
a11
(FL2FALNP0014),
Kurziflavolactone
C
(FL2FA9NC0016),
Licorice
glycoside
E
(FL2F1AGSN001) and Taxifolin 3'- (6"-phenylacetylglucoside) (FL4DACGS0020) binding only

7

the SBS; Sanggenol O (FL2FALNP0020), CHEMBL2171573, Kanzonol E (FL3F1ANP0001),
CHEMBL2171584 and Abyssynoflavanone VI (FL2FACNP0014) binding only the DS;
CHEMBL2171598, CHEMBL2171577, Denticulaflavanol (FL5FAANR0001), Kurzichalcolactone
(FL1CA9NC0001) and CHEMBL2171578 binding only CS (Figure 2). Of these compounds, seven
flavonoids (Licorice glycoside E, Taxifolin 3'- (6"-phenylacetylglucoside), CHEMBL2171573,
CHEMBL2171584, CHEMBL2171598, CHEMBL2171577 and CHEMBL2171578) had more than 12
torsions, while the rest had less than eight torsions.
Table 2. List and 2D structure of top flavonoid hits.
ID
Common name
Site
SMILE

2D-Structure

c(c5O)c(cc(c45)OC(CC(
=O)4)c(c2)c(C1)c(c(O3)
FL2FACNP0014 Abyssinoflavanone VI DS
c2CCC(C)(C)3)OC(C1O)
(C)C)O

FL3F1ANP0001

Kanzonol E

c(c4)(CC=C(C)C)c(cc(c4
DS 3)OC(=CC3=O)c(c1)cc(
C=2)c(OC(C2)(C)C)c1)O

c(OC(O4)C(OC(O5)
C(O)C(COC(=O)c(c
76)cnc6cccc7)(C5)O
FL2F1AGSN001 Licorice glycoside E SBS
)C(C(C4CO)O)O)(c1
)ccc(C(O2)CC(c(c3)
c2cc(c3)O)=O)c1

FL2FALNP0014

FL2FALNP0020

FL3FQUNP0001

Euchrenone a11

O=C(c31)CC(c(c5O)cc(c
4c5)C=CC(O4)(C)C)Oc1
SBS
c(CC=C(C)C)c(c2c3O)O
C(C=C2)(C)C

Sanggenol O

c(C(C4)Oc(c5)c(c(cc5O
)O)C4=O)(c23)cc(c1c(C
DS
=CC(C)(C)O3)2)C=CC(C
)(C)O1

Dorsilurin E

c(c54)(O6)c(CCC6(C)C)
c(c2c4OC(CC5)(C)C)OC
SBS
(=c(c3)c(=O)cc(O)c3)C(
=C21)CCC(C)(C)O1

8

NA

Cc1ccc(COc2cc(OCc3cc
c(C)cc3)cc(DS c3cc(=O)c4ccc(OCC(O)
CNC(C)(C)C)cc4o3)c2)c
c1

NA

CC(C)(C)NCC(O)COc1cc
c2c(=O)cc(CS c3cc(OCc4cc(Cl)cc(Cl)c
4)cc(OCc4cc(Cl)cc(Cl)c
4)c3)oc2c1

NA

O=c1cc(c2cc(OCc3ccccc3)cc(O
CS Cc3ccccc3)c2)oc2cc(O
CC(O)CN3CCN(c4ccccc
4)CC3)ccc12

FL1CA9NC0001

Kurzichalcolactone

c(c5)ccc(c5)C=CC(C3)(
OC(C4)CCCC(Oc(c2C34
CS
)cc(c(c(O)2)C(C=Cc(c1)
cccc1)=O)O)=O)O

FL2FA9NC0016

C(C3=O)CCC(O1)C
C(c(c4O)c(cc(O5)c(
Kurziflavolactone C SBS C(=O)CC(c(c6)cccc
6)5)4)O3)CC1(C=Cc
(c2)cccc2)O

CHEMBL2171573

CHEMBL2171577

CHEMBL2171598

CHEMBL2171578

FL5FAANR0001

CHEMBL2171584

NA

CC(C)NCC(O)COc1ccc2
c(=O)cc(CS c3cc(OCc4cc(Cl)cc(Cl)c
4)cc(OCc4cc(Cl)cc(Cl)c
4)c3)oc2c1

Denticulaflavonol

c(C(O2)=C(C(c(c(O)3)c
2cc(c3CC=C(C)CCC(C5(
CS C)4)C(=C)CCC4C(CCC5)
(C)C)O)=O)O)(c1)ccc(c
1)O

NA

CC(C)(C)NC[C@H](O)C
Oc1ccc2c(=O)cc(DS
c3cc(OCc4ccccc4)cc(O
Cc4ccccc4)c3)oc2c1

c(c1)(O)cc(c(C(=O)2)c1
Taxifolin 3'- (6"OC(c(c3)ccc(O)c(OC(O
FL4DACGS0020 phenylacetylglucosi SBS 4)C(O)C(C(C(COC(Cc(c
de)
5)cccc5)=O)4)O)O)3)C
2O)O
The common name, code, SMILE, 2D structure of each flavonoid is indicated, along with the putative binding site it binds to.

9

10

Main interactions are shown as dotted points: hydrogen bonds in black, p -p or p -cation interactions in orange, and halogen bonds in green.

Figure 2. Interactions of the top 5 binding energy compounds. Putative binding sites are in order of appearance and the ligands are color-coded: induced-fit substrate binding site (1¬∞ row, green), dimerization
site (2¬∞ row, blue) and cryptic site (3¬∞ row, magenta). Ligands are depicted as sticks and protein as cartoon and surface. The common name of each ligand is shown, except for those where only a code is available.

Remarkably, all SBS-binding ligands interacted with one catalytic residue (His41) mentioned in
previous literature (Table 3). Among the most energy-favoured hits for SBS, Dorsilurin E
presented the best binding energy to ISBS (-11.31 kcal/mol). The same compound showed a
binding energy of -9.51 kcal/mol in the NSBS. This compound interacted through a hydrogen
bond with residue Gln192 from ISBS from a 2.06 √Ö distance. Besides, hydrophobic interactions
with residues His41, Met49, Met165, Glu166, Leu167, Pro168, and Gln189 were observed, which
favour complex stabilization. The estimated Kd to the ISBS was 4.78 nM, whereas in the NSBS it
was 100.87 nM, for the best inhibitor.
For DS, Sanggenol O was the single best putative inhibitor with a binding energy of -7.29
kcal/mol and a Kd of 4334.61 nM. This energy value was lower than the binding energies for the
top hits in the other two putative binding sites. Sanggenol O presented four hydrogen bonds
(with residues Met6, Ser113, Gln127 and Arg298 from 2.12, 3.25, 2.60 and 2.21 √Ö distances,
respectively), along with four hydrophobic interactions (Phe8, Pro9, Thr304 and Phe305) (Table
3). Surprisingly, all DS hits inserted at least one of their aromatic rings into a novel pocket
comprised by DS and CS residues Met6, Glu290, Arg298; by residues exclusive to CS: Lys5 and
Val303; and other residues not included in any site: Ala7, Phe8, Ser113, Gln127, Phe291, Asp295
(Figure 3). The cavity is also present in other crystal structures of the free MPRO (PDB IDs: 6XB1,
6XHU, 6Y2E, 6M2Q, 6Y84 and 7BRO). Interestingly, the mentioned pocket disappears in 6LU7
(MPRO complexed with inhibitor N3). However, in other MPROs complexed with different
inhibitors, the novel pocket is present fully or to some degree (PDB IDs: 6M2N, 6WTT, 6XMK,
6M0K, 6W63, 6XBG).

Figure 3. Close-up of the novel pocket in the dimer binding site. The surface of residues comprising the novel pocket are shown in
red, whereas the rest of the protein‚Äôs surface is in cyan. A representative compound from those tested against dimerization and
cryptic sites, CHEMBL2171598, is shown in magenta sticks as it introduces an aromatic ring into the novel cavity.

11

Table 3. Comprehensive list of protein-ligand interactions.
Hydrophobic
Site

Ligand

FL3FQUNP0001
[Dorsilurin E]

Substrate

FL2FALNP0014
[Euchrenone a11]

FL2FA9NC0016
[Kurziflavolactone
C]

Torsions

ŒîG

Ligand
Kd (nM) Residue
atom

1

-9.51* 100.87*
-11.31** 4.78**

5

-9.00* 239.30*
-10.14** 34.70**

5

-8.88* 293.25*
-11.24** 5.38**

His41
Met49
Met165
Glu166
Leu167
Pro168
Gln189
His41
Met49
Phe140
Leu141
Met165
Asp187
Thr25
Leu141
Asn142
Met165
Glu166
Val303
Thr25

FL2F1AGSN001
[Licorice glycoside
E]

FL4DACGS0020
[Taxifolin 3'- (6"phenylacetylglucosi
de)]

FL2FALNP0020
[Sanggenol O]

16

15

3

Dimer

Leu141 O38
O39
Gly143
Gly143
O39
O39 Cys145
O34
His163

1.99
2.36
3.50
1.77
2.23

Thr26

1.86

Phe140
Met165
Glu166
-7.21* 4963.68*
Gln189
-9.27** 151.47**
Gln192

C18
C24
C16
C23
C4

3.25
3.52
3.41
3.51
3.77

Phe8
Pro9
4334.61 Thr304

C23
C6
C12
C3
C18
C28
C11
C7
C15
C30
C30
C37
C27
C3
C25
C24
C4
C16
C24
C25
C22
C6
C25
C12
C10
C15
C10
C11
C35
C37
C35
C3
C20
C28
C20
C14
C7
C8
C25

3.41
3.35
3.70
3.48
3.65
3.92
3.89
3.87
3.16
3.80
3.53
3.34
3.5
3.62
3.46
3.60
3.57
3.29
3.10
3.14
3.07
3.98
3.63
3.45
3.92
3.13
3.67
3.87
3.92
3.27
3.42
3.97
3.87
3.46
3.39
3.49
3.66
3.76
3.68

His41
Gly143
Ser144
O50
Ser144
His 163
Glu166
Gln192
Tyr54
O41
Glu166
O42
O40
O37
Gln192
O30
Ser113
Gln127

3.08
2.44
3.09
2.74
2.93
2.04
3.12
2.54
2.58
2.49
1.80
2.13
2.18
1.99
2.17
44167
3.25
2.60

O31

Arg298

2.21

N1

Ser10

3.28

O42

Ser10

2.35

Ser10
O43
Glu14

O43
Gly11
N1

1.91
2.62
2.61

Met6
O29

O29
Gln127

2.02
3.72

Ser10

N1

1.76

O43
Ser10
O42

Ser10
O43
Ser10

2.79
2.47
2.58

Met6
O30
O30

O30
Ser113
Gln127

2.04
3.23
2.63

O31

Arg298

2.18

-7.29

-7.28

Val125
4408.66 Phe291
Asp295

-6.92

8112.39

Asp295
Arg298
Gln299
Thr304

Pro9

-6.89

Glu14
Leu115
Pro122
8535.30
Val125
Arg298
Gln299

4

1.94
2.02

O42
O43
O50
Ser144
O48
O50
O37
O46
O40
His164
O42
Glu166
Asp187
Thr190
O37
Met6
O30
O30

Phe305

FL2FACNP0014
[Abyssinoflavanone VI]

Glu166 O35
O36 Glu166

O41

Phe291

14

2.06

3.29
3.48
3.68

Gln299

CHEMBL2171584

Gln192

3.37

Phe305
Phe3
Met6
Phe8
Pro9
4

O35

C22
C32
C23

Pro9

FL3F1ANP0001
[Kanzonol E]

3.31
3.94
3.47
3.17
3.99
3.85
3.70
3.81
3.81
3.85
3.41
3.64
3.27
3.82
3.60
3.79
3.55
3.76
3.34
3.07

C15

Phe305

14

C8
C7
C3
C21
C29
C27
C3
C24
C25
C30
C14
C15
C24
C15
C23
C31
C3
C4
C23
C24

Met165
Pro168
-7.69* 2201.31* Gln189
-9.26** 154.06**

Met6

CHEMBL2171573

Hydrogen bond

Distance
Distance
Acceptor Donor
(√Ö)
(√Ö)

-6.83

9448.42

Phe305
Pro9
Thr304
Phe305

Other
Type

œÄ-Cation

Residue

Ligand
Distance
atoms

C8, C9,
C10,
His41
C11,
C12,
C13

5.83

C22,
C23,
C24,
C25,
C26,
C27

4.79

œÄ-Cation Arg298

C25,
C26,
C27,
C28,
C29,
C31

4.81

œÄ-Cation Arg298

C18,
C19,
C20,
C21,
C22,
C23

4.74

C18,
C19,
C20,
C21,
C22,
C23

4.18

œÄ-Stacking His41

œÄ-Stacking Phe8

12

CHEMBL2171598

14

-10.59

16.19

Lys5
Met6
Pro9
Tyr126
Asp295
Gln299
Phe305
Tyr237
Asn238
Tyr239

CHEMBL2171577

14

-10.51

18.54
Leu286

Cryptic

Leu287

FL5FAANR0001
[Denticulaflavonol]

10

-10.44

20.87

Lys137
Thr199
Tyr237
Tyr239
Leu272
Leu286
Leu287

FL1CA9NC0001
[Kurzichalcolactone
]

CHEMBL2171578

8

14

-10.23

-9.97

29.79

46.28

Phe8
Ile213
Asp295
Arg298
Gln299

C41
C21
C4
C44
C22
C21
C30
C15
C32
C37
C35
C33
C7
C21
C23
C7

3.48
3.72
3.14
3.88
3.54
3.63
3.26
3.55
3.93
3.96
3.70
3.78
3.47
3.21
3.14
3.95

C7
C15
C27
C28
C27
C21
C22
C18

3.69
3.85
3.65
3.21
3.28
3.63
3.68
3.52

C29
C22
C31
C26
C2

3.82
2.95
3.75
3.40
3.82

Thr199

C9

3.56

Tyr237
Asn238
Tyr239

C25
C27
C7
C22
C16
C3
C3
C5

3.62
3.44
3.66
3.54
3.70
3.67
3.61
3.57

Leu286
Leu287

Lys5
O49
Val125

O50
Ala7
N1

2.01
2.97
44137

O41

Lys5

1.73

O38
O42

Thr199
Leu287

2.26
2.18

Glu288

N1

2.92

Glu288
O40
O40
O41
O39
Asp197
Glu288
O37

O41
Asp289
Lys5
Gln127
Lys137
O39
O40
Glu288

2.02
2.44
1.97
2.28
1.97
2.13
1.94
2.69

O37

Asp289

1.82

O38 Asp289
O40 Glu290
Gly2
O36
Gln299 O37
Val303
O39
O38
Val303

2.05
3.47
2.04
2.03
1.86
2.25

Donor:
Cl46

3.29

C4, C5,
œÄ-Cation Arg131 C6, C7,
C8, C9

4.03

Halogen

O37

Arg131

2.80

O37
Thr199
O42 Leu287
Glu288
N1

2.08
2.15
3.14

Glu288

1.91

O40

Asp197

œÄ-Cation Arg298

Halogen

Asp197

C29,
C31,
C28,
C30,
C27,
C32

4.55

Donor:
Cl44

3.75

Top 5 binding energy flavonoids are listed for each putative binding site. Interactions are according to PLIP predictions. ‚àÜG and Kd
values for the substrate binding site are marked as * for the normal docking procedure and ** for the induced-fit docking. Note that
both ligand and protein can participate as donor or acceptor in hydrogen bonds. Thus, ligands are represented with their atom name
and number, and protein residues are portrayed as their name and number.

The buried rings of CHEMBL2171584 and CHEMBL2171573 sustain a cation-œÄ interaction with
Arg298 (Figure 2, Table 3). Abyssinoflavanone VI shows a œÄ-œÄ stacking with Phe8. The inserted
rings of Abyssinoflavanone VI, Sanggenol O and Kanzonol E are substituted with hydroxyl groups.
In both Abyssinoflavanone VI and Sanggenol O, the hydroxyl group in the position 5 of the
backbone ring shows hydrogen bonds with Arg298. Likewise, in both flavonoids the hydroxyl
group in the position 7 presents three hydrogen bonds with Met6, Ser113 and Gln127 (Figure
2). Furthermore, the hydroxyl group in the position 7 of the Kanzonol E ring establishes hydrogen
bonds with Met6 and Gln127.
As for the CS, CHEMBL2171598 was the best inhibitor with a binding energy of -10.59 kcal/mol
and a Kd of 16.19 nM. This compound interacted through hydrogen bonds with residues Lys5,
Ala7 and Val125 from 2.01, 2.97 and 2.11 √Ö, respectively (Table 3). Likewise, it held hydrophobic
interactions with residues Lys5, Met6, Pro9, Tyr126, Asp295, Gln299 and Phe305. Interestingly,
Kurzichalcolactone and CHEMBL2171598 were found to bind within the novel pocket in the
same fashion as the DS hits.
The information regarded surface data for each hit is included in Table 4. The widest interface
areas for SBS, DS and CS are observed in Licorice glycoside E with 553.205 √Ö2; CHEMBL2171573
with 484.185 √Ö2; and CHEMBL2171598 with 536.563 √Ö2, respectively.

13

Table 4. Protein/Ligand interface areas.
Site

SBS

DS

CS

Ligand

Name

FL3FQUNP0001
FL2FALNP0014
FL2FA9NC0016
FL2F1AGSN001
FL4DACGS0020
FL2FALNP0020
CHEMBL2171573
FL3F1ANP0001
CHEMBL2171584
FL2FACNP0014
CHEMBL2171598
CHEMBL2171577
FL5FAANR0001
FL1CA9NC0001
CHEMBL2171578

Dorsilurin E
Euchrenone a11
Kurziflavolactone C
Licorice glycoside E
Taxifolin 3'- (6"-phenylacetylglucoside)
Sanggenol O
NA
Kanzonol E
NA
Abyssinoflavanone VI
NA
NA
Denticulaflavonol
Kurzichalcolactone
NA

SBS

Interface Ligand/Protein (√Ö2 )
DS

CS

446.243
455.602
450.332
553.205
452.283

-----------

-----------

-----------

332.971
484.185
360.737
482.063
323.374

-----------

-----------

-----------

536.563
497.366
477.840
428.060
505.758

Measure of the protein/ligand interface areas expressed in √Ö¬≤ for all 15 hit flavonoids with their respective putative binding sites.
Standard deviations provided for comparison.

3.6. Positive and negative controls
The inhibitory ligand X77 successfully docked against the ISBS of the free MPRO (-10.77 kcal/mol).
A structural alignment between the ligands on the docked structure and the original 6W63
crystal revealed a relatively low deviation from the original (RMSD: 1.352 and 1.693 √Ö, with and
without hydrogens, respectively), considering that the docked ligand was not the original
inhibitor (N3) from the employed induced conformation (Figure 4). As for the negative control,
the best pose according to the 2Dscore had an energy of -5.46 kcal/mol.

Figure 4. Structural alignment between the positive control and the original MPRO crystal. Docked inhibitory ligand was aligned to
the original MPRO crystal (PDB: 6W63), revealing an RMSD of 1.352 √Ö. A close-up is provided such as to observe the docked pose in
detail compared to the original position. The MPRO crystal is shown as in Figure 1. The ligand is shown in sticks: orange for the control
and ice blue for the cross-docked X77.

14

4. DISCUSSION
4.1. Structure
The MPRO binding sites analysis have provided new insights regarding the chemical
microenvironments of the structure. Based on the aforementioned pKa‚Äôs of HSD and HSE, the
pH range needed for the coexistence of these two protonation states is 6.7-7.3. Hence, SBS
microenvironment‚Äôs pH is acidic with respect to the pH 7.4 of the general system. Additionally,
His172 is proximate to His163, the latter belonging to SBS. His172 is also protonated in the HSD
position. Given the proximity of these two 6.5 pKa residues (7.6 √Ö between alpha carbons), there
is more reason to believe in the relative acidity of the SBS. Moreover, the presence of two
adjacent histidines with divergent tautomeric states (His163 in HSD and His164 in HSE) suggests
said microenvironment can be further divided, being the region around His163 (S1) more acidic
than the region around His164 (S2). Said difference is reasonable as His163 is closer to the
catalytic subsite S1‚Äô. This acidic microenvironment could ease proteolysis as it has been reported
that the optimum pH range for catalytic sites in other cysteine-proteases is 5-6 (58‚Äì60). Sizeable
changes in the microenvironment pH could thus lead to partial or total loss of catalytic function.
Therefore, a ligand designed to not just bind the SBS but to change local pH is a hypothetical,
but realistic goal for drug designers.
Similar conditions are found in a DS subregion comprising Ser139, Phe140 and Glu166. His163
and His172, close to the aforementioned DS subregion, are in HSD tautomeric state, suggesting
an acidic microenvironment for this DS subsection. In contrast, no histidines were observed near
or within the CS.
Then, Table 1 shows CS has the highest number of charged residues and thus stands a better
chance of establishing saline bonds with an appropriate ligand. The absence of this type of
interaction among the other compounds is explained by the electrochemically neutral nature of
the hits. Future attempts at drug design might benefit from avoiding electrochemical neutrality
for a greater chance of saline bond formation in this region.
4.2. Docking
As has already been mentioned, Table 3 contains binding energies which suggest likelihood of
effective binding. To take these numbers at face value could be misleading, however. Besides
binding energy, binding location and interaction density should also be accounted for. In
particular, for the SBS docking, the more subsites a ligand interacts with in a wider area, the
higher the chance of proper inhibition, as the cavities needed for the proper accommodation of
the natural substrate of MPRO would be sterically obstructed.
For instance, besides a handsome binding energy, Dorsilurin E forms one hydrogen bond and
seven hydrophobic interactions with five different SBS subsites (S1‚Äô, S2, S3, S4 and S5) (Figure
3). By contrast, Euchrenone a11 forms two hydrogen bonds but with the same residue, although
hydrophobic interactions are found in fewer subsites (S1‚Äô, S1, S2 and S3). Similarly,
Kurziflavolactone C has five hydrogen bonds, seven hydrophobic interactions (two with the same
residue) and a cation-œÄ interaction, but only maintains contact with S1‚Äô, S1 and S3 besides two
residues outside SBS proper. Although they present the least binding energy, Licorice glycoside
E and Taxifolin 3'-(6"-phenylacetylglucoside) presented the most hydrogen bonds in the SBS
(nine and seven, respectively). Licorice glycoside E interacts thus with S1‚Äô, S1, S3 and S4 and via
hydrophobic interactions with S3, S4 and S5. Besides, it holds a hydrogen bond and a
hydrophobic interaction with two separate residues outside SBS proper. Taxifolin 3'-(6"phenylacetylglucoside) holds hydrogen bonds with S2, S3 and S4; hydrophobic interactions with
15

S1, S3 and S4; and a œÄ-stacking with S1‚Äô. Because a wider array of subsites could enhance steric
competitiveness, Licorice glycoside E stands a substantial chance at inhibition despite not
showing the greatest binding energy.
It is worth noting all the SBS hits show hydrophobic interactions with Glu166, a residue which
interacts with the N-terminus domain of the second protomer (56). This intercatenary
interaction allows for the stabilization of SBS conformation (in the S1 subsite), which is necessary
for MPRO proteolytic activity (61,62). Based on this, it is highly likely that ligands interacting with
Glu166 may cause structural modifications on the catalytic site and hinder activity. In addition,
œÄ-œÄ stacking interactions were observed between two compounds, Kurziflavolactone C and
Taxifolin 3'-(6"-phenylacetylglucoside), and His41, the latter being one of the catalytic residues
of SBS. His41 is protonated as HSD. Said tautomer prevails in this region‚Äôs acidic pH. A slight
variation in this microenvironment could change the protonation states and modify the
aforementioned interaction. For example, a change in His41 from HSD (single protonation) to
HIS+ (double protonation) could intensify bond interaction (63). However, œÄ-œÄ stackings are
generally weak. Further insights are needed to assess the real contribution to ligand binding by
these interactions.
A last note-worthy point on SBS is that two hits involve glycosylated flavonoids (Licorice
glycoside E and Taxifolin 3'-(6"-phenylacetylglucoside)). A previous study on SARS-CoV-1 3CLPRO
reported two glycosylated flavonoids as inhibitors, whose sugar moieties interacted with the
active sites‚Äôs S1 and S2 subsites through hydrogen bonds (31). Nonetheless, only Licorice
glycoside E‚Äôs sugar moieties exhibited any interactions whatsoever: hydrogen bonds with His41
(S1‚Äô), Gly143 (S1‚Äô), Ser144 (S1‚Äô), His 163 (S1) and Gly166 (S3). While the visualization tools
suggested a non-interactional occupation of S3 by Taxifolin 3'-(6"-phenylacetylglucoside), there
is stark contrast with the results reported by the aforementioned study. The differences in sugarreceptiveness between analogous subsites could be illuminating for future studies aiming at
deeper comparative analyses between both proteases.
Further along the line, the MPRO DS is presented as a remarkably druggable site for possible
inhibition, since a close correlation between the dimerization process and the proteolytic
activity has been indicated (64). Remarkably, all the DS hits interacted with highly conserved
residues among coronaviruses, namely Arg4, Met6, Gly11, Gly14, Ser10, and Arg298 (32). Under
this view, hydrogen bonds might interfere with the dimerization and might be key for future
coronavirus inhibitors development (Figure 2, Table 3). Remarkably, all the DS hits interacted at
least one of the DS residues which are highly conserved among coronaviruses, namely Arg4,
Met6, Gly11, Gly14, Ser10, and Arg298 (32) (Table 3).
Additionally, the binding modes observed in those compounds revealed a cavity partially
spanning both DS and CS showing high affinity for substituted and unsubstituted aromatic rings.
According to the ring‚Äôs substitutions, the pocket would allow for œÄ-œÄ and cation-œÄ interactions
as well as hydrogen bonds. Both cation-œÄ interactions and hydrogen bonds involve at least one
polar group whereas œÄ-œÄ stackings could be present between exclusively nonpolar groups. As
the novel pocket has the possibility to form any of these interactions, it must have affinity for
both nonpolar or polar moieties. Therefore, the novel pocket has an amphipathic nature. This is
coherent with the other results, as the introduced rings can be either hydrophobic (phenyl rings)
or hydrophilic (phenyl rings substituted with hydroxyl groups).
The CS may be visually divided in two regions: the first comprised by residues shared with the
novel pocket (Lys5, Met6, Gln290, Arg298 and Val303), and the second conformed by the
remaining residues (Pro108, Gly109, Arg131, Trp218, Phe219, Tyr239, Glu240, Leu271, Leu272,
Leu287, Glu288, Asp289, Glu290 and Gln299). Five of the 11 novel pocket residues are shared
16

with the CS, and thus have higher CryptoSite scores than the recommended threshold (28).
Although this suggests a cryptic nature for this new cavity, further analysis to confirm the reality
of the pocket is wanting. By definition, a cryptic site is one that forms in holo structure, but not
in the apo structure (28). As the novel cavity was also present in the apo structure of some
crystal structures of the MPRO (PDB IDs: 6XB1, 6XHU, 6Y2E, 6M2Q, 6Y84 and 7BRO it would be
necessary to see a dramatic modification of this region upon ligand binding over time. Cavity
expansion and ligand engulfing upon binding would count as sufficient evidence to formally
propose the cavity as a novel cryptic site. Thus, it would be reasonable to submit the systems of
the presented best hits to molecular dynamics simulations. Such a method would allow us to
evaluate the systems‚Äô mechanics and free energy profiles. In contrast to apo-MPRO, where a free
energy local minimum is expected at the novel pocket region, it is presumed that the hits that
interacted with said region are able to induce a higher energy conformation and stabilize the
pocket (65).
Unlike the novel pocket, the second CS region forms no observable cavity in the apo-MPRO. If a
cavity is then formed upon ligand binding, this region would fit the definition of cryptic site
better than the novel pocket. However, as it is the case with the novel cavity, to see this
formation and settle the cryptic nature of this second region, it would be necessary to submit
the systems to molecular dynamics.
In other considerations, binding energy is not the only factor to take into account, as interface
area between ligand and protein in complex is important as well. In short, more interface area
involves less SASA, as the ligand buries more protein area. A greater interface area generally
enjoys three advantages. First, the ability to sterically compete with the native substrate for the
SBS is enhanced as less SASA is present for the natural substrate after the binding event. This
fact is closely related to the previously mentioned occupation of the SBS subsites. Second, as
the ligand occupies more protein surface, more interfacial water is dispersed and ‚Äúreinserted‚Äù
into the solvent, thus partly offsetting the entropic diminishment from ligand binding and
preserving the second law of thermodynamics (66). Another contribution to this compensation
is an increase in the number of conformational degrees of freedom of the protein itself (67,68).
This is the third advantage: a wider contact surface area for the ligand might make it easier to
alter the native enzyme conformation for the MPRO and achieve more degrees of freedom. Said
correlation has been observed both in protein-protein complexes (69) and individual subunits
(70) as a relation between interface surface and sizable conformational change (71). It is
suggestive to imagine a similar relationship with regard to protein-ligand complexes. Therefore,
while there is not much difference among the interface areas projected by SBS and CS ligands,
DS ligands show greater standard deviation.If interface area is therefore taken as an important
variable for inhibition, Licorice glycoside E and CHEMBL2171598 could be most promising for
SBS and CS, respectively.
5. CLOSING REMARKS
Flavonoids have already been suggested as potential inhibitors of the SARS-CoV MPRO, showing
a high affinity for their hydrophobic aromatic rings and hydrophilic hydroxyl groups (31). In the
present research, a group of 15 flavonoids has been identified as possible SARS-CoV-2 MPRO
inhibitors. Said group shares some structural similarities with those proposed as SARS-CoV-1
inhibitors. Besides, these compounds have been evaluated against different binding sites in MPRO
(SBS, DBS and CBS), and the resulting binding energies were favourable for flavonoid-protein
complexes.

17

Molecular dynamics of the 15 compounds with their respective putative binding sites are
currently under way. Moreover, the complete, dimeric structure of MPRO is being considered for
SBS as this site is stabilized by both protomers (61,62). Nonetheless, experimental validations
are still required to vouch for the effectiveness of the presented compounds as true SARS-CoV2 inhibitors. Not only PAINS, but colloidal aggregates could induce false positives (53,54), calling
for the application of surface tension reduction agents such as Triton-X100 or Tween-80 (72,73).
6. ACKNOWLEDGEMENTS
We thank Dr. Miguel Quiliano for sharing his pearls of wisdom with us during the course of this
research. We would also like to show our gratitude to the Universidad Privada San Juan Bautista
and Mr. Guido Choque for their logistical support.
7. REFERENCES
1.

Novel Coronavirus(2019-nCoV) Situation Report-22 [Internet]. 2020 [cited 2020 May 25].
Available from: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2

2.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020 Feb 15 [cited 2020 May
25];395(10223):497‚Äì506.
Available
from:
https://linkinghub.elsevier.com/retrieve/pii/S0140673620301835

3.

Zhao Z. Description and clinical treatment of an early outbreak of severe acute respiratory
syndrome (SARS) in Guangzhou, PR China. J Med Microbiol [Internet]. 2003 Aug 1 [cited
2020
May
25];52(8):715‚Äì20.
Available
from:
https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.05320-0

4.

Patrick Walters W, Stahl MT, Murcko MA. Virtual screening - An overview. Drug Discov
Today. 1998 Apr 1;3(4):160‚Äì78.

5.

Kumar A, Zhang KYJ. Hierarchical virtual screening approaches in small molecule drug
discovery. Methods. 2015 Jan 1;71(C):26‚Äì37.

6.

Tanrikulu Y, Kr√ºger B, Proschak E. The holistic integration of virtual screening in drug
discovery. Vol. 18, Drug Discovery Today. Elsevier Current Trends; 2013. p. 358‚Äì64.

7.

Ruddigkeit L, Van Deursen R, Blum LC, Reymond JL. Enumeration of 166 billion organic
small molecules in the chemical universe database GDB-17. J Chem Inf Model.
2012;52(11):2864‚Äì75.

8.

Lin A, Horvath D, Afonina V, Marcou G, Reymond J-L, Varnek A. Mapping of the Available
Chemical Space versus the Chemical Universe of Lead-Like Compounds. ChemMedChem
[Internet]. 2018 Mar 20 [cited 2020 Jun 6];13(6):540‚Äì54. Available from:
http://doi.wiley.com/10.1002/cmdc.201700561

18

9.

Meza Menchaca T, Ju√°rez-Portilla C, C. Zepeda R. Past, Present, and Future of Molecular
Docking. In: Drug Discovery and Development - New Advances. IntechOpen; 2020.

10.

Sethi A, Joshi K, Sasikala K, Alvala M. Molecular Docking in Modern Drug Discovery:
Principles and Recent Applications. In: Drug Discovery and Development - New Advances.
IntechOpen; 2020.

11. Fan J, Fu A, Zhang L. Progress in molecular docking. Vol. 7, Quantitative Biology. Higher
Education Press; 2019. p. 83‚Äì9.
12. Murgueitio MS, Bermudez M, Mortier J, Wolber G. In silico virtual screening approaches for
anti-viral drug discovery. Vol. 9, Drug Discovery Today: Technologies. Elsevier Ltd; 2012.
p. e219‚Äì25.
13. Mallipeddi P, Kumar G, White S, Webb T. Recent Advances in Computer-Aided Drug Design
as Applied to Anti-Influenza Drug Discovery. Curr Top Med Chem. 2014 Oct
1;14(16):1875‚Äì89.
14. Karthick V, Nagasundaram N, Doss CGP, Chakraborty C, Siva R, Lu A, et al. Virtual screening
of the inhibitors targeting at the viral protein 40 of Ebola virus. Infect Dis Poverty
[Internet]. 2016 Feb 17 [cited 2020 Jun 6];5(1):12. Available from:
http://www.idpjournal.com/content/5/1/12
15. Tahir ul Qamar M, Maryam A, Muneer I, Xing F, Ashfaq UA, Khan FA, et al. Computational
screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors
against dengue virus. Sci Rep. 2019 Dec 1;9(1):1‚Äì16.
16. Zhang H, Saravanan KM, Yang Y, Hossain T. Deep learning based drug screening for novel
coronavirus 2019-nCov. Prepr. 2020 Feb 5;19(8):1‚Äì17.
17. Li Y, Zhang J, Wang N, Li H, Shi Y, Guo G, et al. Therapeutic Drugs Targeting 2019-nCoV Main
Protease by High-Throughput Screening. bioRxiv [Internet]. 2020 Jan 30 [cited 2020 Jun
6];2020.01.28.922922.
Available
from:
https://www.biorxiv.org/content/10.1101/2020.01.28.922922v2
18. Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH. An overview of severe acute
respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics
and small molecule chemotherapy. Vol. 59, Journal of Medicinal Chemistry. American
Chemical Society; 2016. p. 6595‚Äì628.
19. Raugi DN, Smith RA, Gottlieb GS. Four Amino Acid Changes in HIV-2 Protease Confer ClassWide Sensitivity to Protease Inhibitors. J Virol. 2016 Jan 15;90(2):1062‚Äì9.
20. Xu Z, Peng C, Shi Y, Zhu Z, Mu K, Wang X, et al. Nelfinavir was predicted to be a potential
inhibitor of 2019-nCov main protease by an integrative approach combining homology
modelling, molecular docking and binding free energy calculation. bioRxiv [Internet]. 2020

19

Jan
28
[cited
2020
Jun
7];2020.01.27.921627.
https://www.biorxiv.org/content/10.1101/2020.01.27.921627v1

Available

from:

21. Liu X, Wang X-J. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically
approved medicines. bioRxiv. 2020 Jan 29;2020.01.29.924100.
22. Chen YW, Yiu C-PB, Wong K-Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease
(3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug
repurposing candidates. F1000Research. 2020 Apr 9;9:129.
23. Vedani A, Dobler M, Hu Z, Smie≈°ko M. OpenVirtualToxLab-A platform for generating and
exchanging in silico toxicity data. Toxicol Lett. 2015 Jan 2;232(2):519‚Äì32.
24.

Fischer A, Sellner M, Neranjan S, Lill MA, Smie≈°ko M. Inhibitors for Novel Coronavirus
Protease Identified by Virtual Screening of 687 Million Compounds. ChemRxiv Prepr. 2020
Mar 3;1‚Äì21.

25.

Davis DA, Tebbs IR, Daniels SI, Stahl SJ, Kaufman JD, Wingfield P, et al. Analysis and
characterization of dimerization inhibition of a multi-drug-resistant Human
Immunodeficiency Virus Type 1 protease using a novel size-exclusion chromatographic
approach. Biochem J. 2009 Apr 15;419(2):497‚Äì506.

26. Shahian T, Lee GM, Lazic A, Arnold LA, Velusamy P, Roels CM, et al. Inhibition of a viral
enzyme by a small-molecule dimer disruptor. Nat Chem Biol. 2009;5(9):640‚Äì6.
27. Vajda S, Beglov D, Wakefield AE, Egbert M, Whitty A. Cryptic binding sites on proteins:
definition, detection, and druggability. Curr Opin Chem Biol [Internet]. 2018 Jun 1 [cited
2020 Jun 26];44:1‚Äì8. Available from: /pmc/articles/PMC6088748/?report=abstract
28. Cimermancic P, Weinkam P, Rettenmaier TJ, Bichmann L, Keedy DA, Woldeyes RA, et al.
CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of
Cryptic Binding Sites. J Mol Biol [Internet]. 2016 Feb;428(4):709‚Äì19. Available from:
http://dx.doi.org/10.1016/j.jmb.2016.01.029
29. Beglov D, Hall DR, Wakefield AE, Luo L, Allen KN, Kozakov D, et al. Exploring the structural
origins of cryptic sites on proteins. Proc Natl Acad Sci U S A. 2018;115(15):E3416‚Äì25.
30.

Mucsi I, Gyulai Z, B√©l√°di I. Combined effects of flavonoids and acyclovir against
herpesviruses in cell cultures. Acta Microbiol Hung. 1992 Jan 1;39(2):137‚Äì47.

31. Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme
Inhib
Med
Chem
[Internet].
2020;35(1):145‚Äì51.
Available
from:
https://doi.org/10.1080/14756366.2019.1690480
32. Chen YW, Yiu C-PB, Wong K-Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease
(3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug
repurposing candidates. F1000Research [Internet]. 2020 Apr 9 [cited 2020 May 25];9:129.
Available from: https://f1000research.com/articles/9-129/v2
20

33. Jitendra Subhash R, Aroni C, Abhijeet K, Shashikant R. Targeting SARS-CoV-2 Spike Protein
of COVID-19 with Naturally Occurring Phytochemicals: An in Silco Study for Drug
Development. chemRxiv [Internet]. 2020 Apr 9 [cited 2020 Jun 26]; Available from:
https://chemrxiv.org/articles/Targeting_SARS-CoV-2_Spike_Protein_of_COVID19_with_Naturally_Occurring_Phytochemicals_An_in_Silco_Study_for_Drug_Developm
ent/12094203
34.

Arita M, Suwa K. Search extension transforms Wiki into a relational system: A case for
flavonoid metabolite database. BioData Min [Internet]. 2008 Dec 17 [cited 2020 Jun
26];1(1):7. Available from: http://metabolomics.jp/wiki/Category:FL

35. Wickham H. Easily Harvest (Scrape) Web Pages [R package rvest version 0.3.5]. [cited 2020
Jun 26]; Available from: https://cran.r-project.org/package=rvest
36. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major
update to the DrugBank database for 2018. Nucleic Acids Res [Internet]. 2018 Jan 4 [cited
2020 Jun 26];46(D1):D1074‚Äì82. Available from: https://www.drugbank.ca/
37. Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, et al. ChEMBL web
services: streamlining access to drug discovery data and utilities. Nucleic Acids Res
[Internet]. 2015 Jul 1 [cited 2020 Jun 26];43(W1):W612‚Äì20. Available from:
https://www.ebi.ac.uk/chembl/
38. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2019 update: improved
access to chemical data. Nucleic Acids Res [Internet]. 2019 Jan 8 [cited 2020 Jun
26];47(D1):D1102‚Äì9. Available from: https://pubchem.ncbi.nlm.nih.gov/
39. Lagorce D, Bouslama L, Becot J, Miteva MA, Villoutreix BO. FAF-Drugs4: Free ADME-tox
filtering computations for chemical biology and early stages drug discovery.
Bioinformatics [Internet]. 2017 Nov 15 [cited 2020 Aug 25];33(22):3658‚Äì60. Available
from: www.chemaxon.com
40. O‚ÄôBoyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel:
An Open chemical toolbox. J Cheminform [Internet]. 2011 Oct 7 [cited 2020 Jun
26];3(10):1‚Äì14. Available from: https://link.springer.com/articles/10.1186/1758-2946-333
41. Debye P. N√§herungsformeln f√ºr die Zylinderfunktionen f√ºr gro√üe Werte des Arguments und
unbeschr√§nkt ver√§nderliche Werte des Index. Math Ann [Internet]. 1909 Dec 1 [cited 2020
Jun 26];67(4):535‚Äì58. Available from: http://link.springer.com/10.1007/BF01450097
42.

Gimeno A, Mestres-Truyol J, Ojeda-Montes MJ, Macip G, Saldivar-Espinoza B, CeretoMassagu√© A, et al. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARSCoV-2 through Consensus Docking and Drug Reposition. Int J Mol Sci [Internet]. 2020 May
27 [cited 2020 Jul 16];21(11):3793. Available from: https://www.mdpi.com/14220067/21/11/3793

21

43. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, et al. PDB2PQR: expanding
and upgrading automated preparation of biomolecular structures for molecular
simulations. Nucleic Acids Res [Internet]. 2007 May 8;35(Web Server):W522‚Äì5. Available
from: https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkm276
44. Schr√∂dinger L. The PyMOL Molecular Graphics System, Version 2.4.
45. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and
discovery of its inhibitors. Nature [Internet]. 2020 Jun 11 [cited 2020 Jul
16];582(7811):289‚Äì93. Available from: https://doi.org/10.1038/s41586-020-2223-y
46. Morris GM, Ruth H, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Software news
and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor
flexibility. J Comput Chem [Internet]. 2009 Dec 1 [cited 2020 Jun 26];30(16):2785‚Äì91.
Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jcc.21256
47. Eastman P, Swails J, Chodera JD, McGibbon RT, Zhao Y, Beauchamp KA, et al. OpenMM 7:
Rapid development of high performance algorithms for molecular dynamics. Gentleman
R, editor. PLOS Comput Biol [Internet]. 2017 Jul 26 [cited 2020 Jun 26];13(7):e1005659.
Available from: https://dx.plos.org/10.1371/journal.pcbi.1005659
48. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new
scoring function, efficient optimization, and multithreading. J Comput Chem [Internet].
2009
Jan
30
[cited
2020
Jun
26];31(2):NA-NA.
Available
from:
https://onlinelibrary.wiley.com/doi/full/10.1002/jcc.21334
49. Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein‚Äìligand
docking and virtual drug screening with the AutoDock suite. Nat Protoc [Internet]. 2016
May 14;11(5):905‚Äì19. Available from: http://www.nature.com/articles/nprot.2016.051
50. Santos-martins D, Solis-vasquez L, Koch A, Forli S. Accelerating AUTODOCK 4 with GPUs and
Gradient-Based Local Search. ChemRxiv [Internet]. 2019 Aug 23 [cited 2020 Jun 26];(6).
Available
from:
https://chemrxiv.org/articles/Accelerating_AutoDock4_with_GPUs_and_GradientBased_Local_Search/9702389
51. Blanco Capurro JI, Di Paola M, Gamarra MD, Mart√≠ MA, Modenutti CP. An efficient use of Xray information, homology modeling, molecular dynamics and knowledge-based docking
techniques to predict protein‚Äìmonosaccharide complexes. Glycobiology [Internet]. 2019
Feb
1;29(2):124‚Äì36.
Available
from:
https://academic.oup.com/glycob/article/29/2/124/5165567
52. Bell EW, Zhang Y. DockRMSD: an open-source tool for atom mapping and RMSD calculation
of symmetric molecules through graph isomorphism. J Cheminform [Internet]. 2019 Dec
7;11(1):40.
Available
from:
https://jcheminf.biomedcentral.com/articles/10.1186/s13321-019-0362-7

22

53. Coan KED, Maltby DA, Burlingame AL, Shoichet BK. Promiscuous aggregate-based inhibitors
promote enzyme unfolding. J Med Chem [Internet]. 2009 Apr 9 [cited 2020 Aug
22];52(7):2067‚Äì75. Available from: /pmc/articles/PMC2664636/?report=abstract
54. Ganesh AN, Donders EN, Shoichet BK, Shoichet MS. Colloidal aggregation: From screening
nuisance to formulation nuance. Nano Today [Internet]. 2018 Apr 1 [cited 2020 Aug
22];19:188‚Äì200. Available from: /pmc/articles/PMC6150470/?report=abstract
55. Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein‚Äì
ligand interaction profiler. Nucleic Acids Res [Internet]. 2015 Jul 1;43(W1):W443‚Äì7.
Available from: https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkv315
56. Ribeiro J, R√≠os-Vera C, Melo F, Sch√ºller A. Calculation of accurate interatomic contact surface
areas for the quantitative analysis of non-bonded molecular interactions. Valencia A,
editor. Bioinformatics [Internet]. 2019 Sep 15;35(18):3499‚Äì501. Available from:
https://doi.org/10.1093/bioinformatics/btz062
57.

Kyte JE. Structure in Protein Chemistry [Internet]. Second Edi. UC San Diego Previously
Published Works; 2007. Available from: https://escholarship.org/uc/item/4kv007vf

58. Abdulaal WH. Purification and characterization of cysteine protease from miswak Salvadora
persica. BMC Biochem [Internet]. 2018 Dec 3 [cited 2020 Jul 16];19(1). Available from:
/pmc/articles/PMC6276148/?report=abstract
59.

Jinka R, Ramakrishna V, Rao SK, Rao RP. Purification and characterization of cysteine
protease from germinating cotyledons of horse gram. BMC Biochem [Internet]. 2009
[cited
2020
Jul
16];10(1):28.
Available
from:
/pmc/articles/PMC2784799/?report=abstract

60. Nagarathnam R, Rengasamy A, Balasubramanian R. Purification and properties of cysteine
protease from rhizomes of Curcuma longa (Linn.). J Sci Food Agric [Internet]. 2010 Jan 15
[cited
2020
Jul
16];90(1):97‚Äì105.
Available
from:
https://pubmed.ncbi.nlm.nih.gov/20355018/
61. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARSCoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors.
Science (80- ) [Internet]. 2020 Apr 24 [cited 2020 Jul 15];368(6489):409‚Äì12. Available
from: http://science.sciencemag.org/
62. Goyal B, Goyal D. Targeting the Dimerization of the Main Protease of Coronaviruses: A
Potential Broad-Spectrum Therapeutic Strategy [Internet]. Vol. 22, ACS combinatorial
science. NLM (Medline); 2020 [cited 2020 Jul 16]. p. 297‚Äì305. Available from:
https://dx.doi.org/10.1021/acscombsci.0c00058
63. Liao SM, Du QS, Meng JZ, Pang ZW, Huang RB. The multiple roles of histidine in protein
interactions. Chem Cent J. 2013;7(1):9‚Äì11.

23

64. G C. Quaternary Structure of the SARS Coronavirus Main Protease. Mol Biol Sars-coronavirus
[Internet]. 2020 Apr 24 [cited 2020 Jul 16];115‚Äì28. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176230/?tool=EBI
65. Oleinikovas V, Saladino G, Cossins BP, Gervasio FL. Understanding Cryptic Pocket Formation
in Protein Targets by Enhanced Sampling Simulations. J Am Chem Soc [Internet]. 2016 Nov
2
[cited
2020
Jul
20];138(43):14257‚Äì63.
Available
from:
https://pubs.acs.org/sharingguidelines
66.

I J, HR B. Isothermal titration calorimetry and differential scanning calorimetry as
complementary tools to investigate the energetics of biomolecular recognition. J Mol
Recognit [Internet]. 1999 [cited 2020 Jul 15];12(1). Available from:
https://pubmed.ncbi.nlm.nih.gov/10398392/

67.

MacRaild CA, Daranas AH, Bronowska A, Homans SW. Global Changes in Local Protein
Dynamics Reduce the Entropic Cost of Carbohydrate Binding in the Arabinose-binding
Protein. J Mol Biol. 2007 May 4;368(3):822‚Äì32.

68.

Stockmann H, Bronowska A, Syme NR, Thompson GS, Kalverda AP, Warriner SL, et al.
Residual Ligand Entropy in the Binding of p-Substituted Benzenesulfonamide Ligands to
Bovine Carbonic Anhydrase II. J Am Chem Soc [Internet]. 2008 Sep 17 [cited 2020 Jul
15];130(37):12420‚Äì6. Available from: https://pubs.acs.org/sharingguidelines

69. Janin J, Miller S, Chothia C. Surface, subunit interfaces and interior of oligomeric proteins. J
Mol Biol [Internet]. 1988 Nov 5 [cited 2020 Jul 16];204(1):155‚Äì64. Available from:
https://pubmed.ncbi.nlm.nih.gov/3216390/
70. Conte L Lo, Chothia C, Janin J. The atomic structure of protein-protein recognition sites. J
Mol Biol [Internet]. 1999 Feb 5 [cited 2020 Jul 16];285(5):2177‚Äì98. Available from:
https://pubmed.ncbi.nlm.nih.gov/9925793/
71.

Marsh JA, Teichmann SA. Relative solvent accessible surface area predicts protein
conformational changes upon binding. Structure [Internet]. 2011 Jun 8 [cited 2020 Aug
4];19(6):859‚Äì67. Available from: /pmc/articles/PMC3145976/?report=abstract

72. Irwin JJ, Shoichet BK. Docking Screens for Novel Ligands Conferring New Biology. J Med
Chem
[Internet].
2016
May
12;59(9):4103‚Äì20.
Available
from:
https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b02008
73.

Reker D, Bernardes GJL, Rodrigues T. Computational advances in combating colloidal
aggregation in drug discovery. Nat Chem [Internet]. 2019 May 15;11(5):402‚Äì18. Available
from: http://www.nature.com/articles/s41557-019-0234-9

24

